Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amezalpat + Atezolizumab + Bevacizumab in First-Line Advanced HCC
NCT06680258Phase 3Not yet recruiting
- Sponsor
- Tempest Therapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of amezalpat in hepatocellular carcinoma (HCC), sponsored by Tempest Therapeutics. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
amezalpat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06680258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680258.